Solid Tumor
Conditions
Keywords
solid tumors, Refnot
Brief summary
The study was planned to include disseminated patients with various solid tumors (melanoma, soft tissue sarcoma, breast cancer, colon cancer, etc.). The study drug was administered subcutaneously at a dose of 400,000 IU once a day, 3 times a week (every other day), for 4 weeks. In the absence of disease progression - an additional 4 weeks.
Detailed description
The study was planned to include 50 disseminated patients with various solid tumors. The patients were divided into 2 groups: 1 - Refnot, monotherapy, 2 - Refnot together with chemotherapy. Refnot is administered at a dose of 400,000 IU subcutaneously 3 times a week for 4 weeks. 4 weeks constitute 1 course of treatment with Refnot. Immediately before use, 1 ml of water for injection is added to 4 vials (100,000 IU each) or to a vial containing 400,000 IU. After dilution, the drug is injected subcutaneously into the outer surface of the shoulder or thigh. Injection sites should alternate. In the absence of progression of the disease - an additional 4 weeks. Chemotherapy may be used after 4-8 weeks of Refnot use.
Interventions
DRUGTumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)
has a direct antitumor effect in vitro and in vivo on various tumor cell lines
DRUGTumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy
Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
Sponsors
Refnot-Pharm Ltd
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients who have exhausted standard methods of treatment. * Morphological (histological or cytological) confirmation of the diagnosis. * Age no more than 75 years. * General condition 0-2 (WHO). * Estimated life expectancy of at least 3 months. * Consent to treatment under this protocol. * The number of granulocytes is more than 2000/mm, platelets are more than 150000/mm. * The level of creatinine should not exceed 1.5 norms, liver enzymes (ALT, AST and alkaline phosphatase) should not exceed 3 norms. * For common disease, patients should receive standard treatment earlier.
Exclusion criteria
* Severe manifestations of cardiovascular diseases in the past and at present (myocardial infarction, hypertension, stroke, phlebothrombosis, coronary insufficiency requiring drug control, etc.). * Peptic ulcer of the stomach, duodenal ulcer (in the acute phase), uncorrected diabetes mellitus. * Mental illness preventing understanding of the treatment plan. * Pregnancy. * Metastases of a malignant tumor in the brain (according to clinical data). * Chronic use of corticosteroids or immunosuppressants. * Various neurological diseases that prevent this treatment. * Known allergic reactions and/or other significant allergic conditions. * Any immunotherapy within the last 6 weeks prior to enrollment in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the level of CD3+-cells | 4 weeks | An increase in the level of CD3+-cells relative to the initial |
| Change in the level of CD4+-cells | 2 weeks | An increase in the level of CD4+-cells relative to the initial |
| Change in the level of CD8+-cells | 2 weeks | An increase in the level of T-lymphocytes relative to the initial one in those patients in whom it was reduced |
| Change in the ratio of CD4+/CD8+ | 2 weeks | Increase in the ratio of lymphocytes / lymphocytes relative to the initial |
| Change in NK-cell activity | 4 weeks | Increased activity of NK cells in patients with an initially reduced rate |
Outcome results
None listed